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Abstract
Cancer progression is a complex process involving host-tumor interactions by multiple molecular
and cellular factors of the tumor microenvironment. Tumor cells that challenge immune activity
may be vulnerable to immune destruction. To address this question we have directed major efforts
towards data integration and developed and installed a database for cancer immunology with more
than 1700 patients and associated clinical data and biomolecular data. Mining of the database
revealed novel insights into the molecular mechanisms of tumor-immune cell interaction. In this
paper we present the computational tools used to analyze integrated clinical and biomolecular data.
Specifically, we describe a database for heterogenous data types, the interfacing bioinformatics and
statistical tools including clustering methods, survival analysis, as well as visualization methods.
Additionally, we discuss generic issues relevant to the integration of clinical and biomolecular data,
as well as recent developments in integrative data analyses including biomolecular network
reconstruction and mathematical modeling.
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Background
Despite extensive characterization of environmental and
intrinsic and underlying mechanisms [1,2], markers of
the oncogenic process remain so far poorly predictive of
patient survival and fail to prove their reliability in
clinical use. For example, colorectal cancer is one of the
most common malignancies for both men and women
[3]. The rate of localized cancers (stage I-II; UICC-TNM
classification) is about 40% [4,5]. Despite surgery with
curative intent, the risk of recurrence of these early-stage
patients is high (approximately 20-30%). To subject all
of these patients to post-operative chemotherapy may be
inappropriate and costly [6]. Genetic and molecular
tumor prognostic factors have been proposed to identify
patients who may be at risk for recurrence. None has yet
been sufficiently informative for inclusion in clinical
practice [5]. Identification of patients with high-risk of
recurrence is therefore a major clinical issue. However, in
order to develop stratified or personalized strategies for
such complex multifactorial disease it is of importance
to understand how numerous and diverse elements
function together in human pathology. A comprehensive
understanding of cancer requires the integration and
analysis of data not only from the tumor but also its
microenvironment including the immune cells.
Tumors are composed of a complex network of tumor
cells, immune cells, stromal components including
fibroblasts, and a complex vasculature. To grow, invade,
and metastasize, a tumor interacts with its microenvir-
onment, composed of diverse cells of various origins.
The microenvironment contains cells of the immune
system, including inflammatory infiltrates of innate
immunity and infiltrates of the adaptive immune
response. In colorectal cancer, previous studies have
suggested a clinical role of the immune infiltrates [7-11].
In order to investigate the role of the immune infiltrates
and analyze the tumor immunological microenviron-
ment in humans we developed and installed a database
for cancer immunology with more than 1700 patients
and associated clinical data and biomolecular data. By
analyzing the data we showed the importance of early-
metastatic invasion in colorectal cancer and could
pinpoint a novel prognostic marker for survival [10].
We evidenced that the recently characterized immune
cell subpopulation of effector-memory T cells (TEM),
may have a central role in the control of tumor spreading
to lymphovascular and perineural structures but also to
lymph node or distant organs. In subsequent study we
demonstrated the role of the adaptive immune system
for predicting clinical outcome [9]. Furthermore, we
revealed the importance for patient prognosis of the
nature, the functional orientation, the density and the
localization of immune cell populations within the
primary tumor. Thus, adaptive immune reaction and
intratumoral T-cell subpopulations were better predictor
of survival than traditional staging based on a cancer's
size and spread [9].
In the light of these studies it was of utmost importance
to integrate the data and develop tools for analysis and
visualization. In this paper, we present the solutions
developed to analyze the tumor immunological micro-
environment in humans including database, analytical
tools, and tools for visualization. Specifically, we
describe here the database for clinical and biomolecular
data, the interfacing bioinformatics and statistical tools
including clustering methods, survival analysis, as well
as visualization methods. Furthermore, we discuss
upcoming developments for integrative data analyses
including biomolecular network reconstruction and
mathematical modeling.
Bioinformatics and statistics tools for cancer
immunology
Database for cancer immunology
The database developed for cancer immunology (Tumor
Microenvironment (TME)) integrates clinical and bio-
molecular data. The underlying relational database
model is designed as a cancer patient oriented database
which takes all the patients anamnesis and clinical and
medical history information into account whereby all
patients are linked to a speci?c hospital. Security issues
were treated in regard to the interest of patients. Ethical,
Legal and Social Implications (ELSI) have been fulfilled
(agreement #903434), security modules implemented,
and anonymous information stored. The patient infor-
mation additionally includes medical problems, surgery
and detailed cancer information. Additionally TME.db
allows the storage of a variety of different high-
throughput experiments including:
• Real-Time TaqMan qPCR gene expression data (Low
density arrays, single probes, T-cell repertoire analysis)
• Microsatellite instability (MSI) and mutations data
• Flow cytometric (FACS) phenotyping data
• Protein quantification (ELISA, Quantibody, cytometric
beads assays) data
• Functional data (proliferation, survival, apoptosis,
migration assays)
• Immunohistochemical data (Tissue Micro Array (TMA)
and whole slide analysis)
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TME.db joins and integrates all different types of data
and stores them in a common place where all the
determined analysis parameters are linked in a clear way
dependent on the sample material and the experiment
type. For accessing all the stored information again
sophisticated query methods were developed in order to
retrieve the data in a pre-modi?ed way, already prepared
for statistical analysis. As of May 2009, the database
incorporates 1784 patients with associated clinical data
with 60 parameters (e.g. tumor staging, treatment, cancer
relapse) and 16400 different material information as
well as biomolecular measurements (including qPCR for
400 genes from 125 patients, 820 FACS parameters from
40 patients, 20 tissue microarray assays for 600 patients).
Software architecture
TME is a multi-tier client-server application and can be
subdivided into different functional modules which
interact as self-contained units according to their defined
responsibilities: presentation tier, business tier and
runtime environment. The presentation tier within TME
is formed by a Web interface, which allows programming
access to parts of the application logic. Thus, on the
client side, a user requires an Internet connection and a
recent Web browser with Java support, available for
almost every platform. The business tier is realized as
view-independent application logic, which stores and
retrieves datasets by communicating with the persistence
layer. The internal management of files is also handled
from a central service component, which persists the
meta-information for acquired files to the database. All
services of this layer are implemented as STRUTS and are
using SITEMESH.
Model driven development
In order to reduce coding and to increase the long term
maintainability, the model driven development environ-
ment AndroMDA is used to generate components of the
persistence layer and recurrent parts from the above
mentioned business layer. AndroMDA accomplishes this
by translating an annotated UML-model into a JEE-
platform-specific implementation using Enterprise Java
Beans (EJB), STRUTS and SITEMESH. Due to the
flexibility of AndroMDA, application external services,
such as the user management system, have a clean
integration in the model. Dependencies of internal
service components on such externally defined services
are cleanly managed by its build system. By changing the
build parameters in the AndroMDA configuration, it is
also possible to support different relational database
management systems. This is because platform specific
code with the same functionality is generated for data
retrieval. Furthermore, technology lock-in regarding the
implementation of the service layers was also addressed
by using AndroMDA, as the implementation of the
service facade can be switched during the build process
from Spring based components to distributed Enterprise
Java Beans. At present, TME is operating on one local
machine and, providing the usage scenarios do not
demand it, this architectural configuration will remain.
However, chosen technologies are known to work on
Web server farms and crucial distribution of the
application among server nodes is transparently per-
formed by the chosen technologies.
Data retrieval, collaboration and data sharing
TME offers search masks which allow keyword based
searching in the recorded projects, experiments and
notes. These results are often discussed with collabora-
tion partners to gain different opinions on the same raw
data. In order to allow direct collaboration between
scientists TME is embedded into a central user manage-
ment system which offers multiple levels of access
control to projects and their associated experimental
data. The sharing of projects can be done on a per-user
basis or on an institutional basis. For small or local
single-user installations, the fully featured user manage-
ment system can be replaced by a file-based user
management which still offers the same functionalities
from the sharing point of view, but lacks institute-wide
functionalities.
Bioinformatics analysis tools
The database was mined using standard bioinformatics
tools. Specifically, qPCR and FACS data were explored
using two-dimensional hierarchical clustering of correla-
tion matrices (i.e. gene-wise correlation of the respective
patient groups [9]). Genesis clustering software was used
to visualize the correlation matrix and to perform
Pearson un-centered hierarchical clustering [12]. This
tool was developed for large-scale gene expression cluster
analysis and integrates various tools for microarray data
analysis such as filters, normalization and visualization
tools, distance measures as well as common clustering
algorithms including hierarchical clustering, self-orga-
nizing maps, k-means, principal component analysis,
and support vector machines [12].
Statistical analysis
Survival analysis provides a statistical framework for the
modeling and statistical analysis of the time to event for
a cohort of patients [13]. Since the distribution of
survival times might have an unusual and often
unknown form, nonparametric Kaplan-Meier estimates
are widely used when censoring is present for the
characterization of groups of patients with different
underlying characteristics, i.e. calculating median survi-
val times and patients at risk after a given period.
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Similarly, the log-rank non-parametric test is used to
check the null hypothesis that at any time point there is
no difference in the probability of the event of interest
between the groups [14]. The magnitude of the
difference and its confidence interval can be calculated
using a Cox proportional hazards model. Furthermore
the effect of a novel biomarker can be adjusted for
traditional parameters if this modeling strategy is used
on several covariates.
TME implements the previous tests within a statistical
analysis module. Calculations are done using the
survival package from R [15] to which TME connects
using RServe [16]. The aim is the automatic detection of
biomarkers or sets of biomarkers that - alone or in
combination with other parameters - are able to
discriminate groups of colorectal cancer patients with
good prognosis from those with bad prognosis for both,
overall and disease-free survival. In particular, TME
provides:
- Kaplan-Meier curves, estimates of the median survival
time and number of patients at risk after a certain time
period for the different groups of patients
- Log-rank test for the analysis of the differences in
survival between groups of patients with different
underlying characteristics
- Univariate Cox proportional hazards model to estimate
the magnitude of the effect of the covariate in survival
- Tools for the categorization of numeric covariates into a
fixed number of levels. This can be useful for the
classification of the patients into groups based on the
biomolecular markers stored in TME for each patient,
such as the expression level of a gene or the number of
cells of a given type found at different locations of the
tumor sample.
Although categorization of the patients into groups
might result in loss of information [17], this is often
done in clinical practice. The way the cut-off is set for
dichotomizing a continuous variable is also controver-
sial: A previously described value or a biologically
justified level can be used as suggested by Altman et al
[18]. In the absence of a biologically sound cut-off value,
using a statistic of the sample (such as the median)
balances the number of cases per group but results in
different levels across studies making the comparison of
results from different groups difficult [17]. Hence, the
analysis must be repeated in an independent cohort of
patients categorized using the cut-off previously selected.
The same is true when using the “minimum p-value”
approach [19], i.e. taking the point yielding the
“maximum” significance between groups. This approach
has additional important problems such as the over-
estimation of the prognostic importance of the covariate
and multiple testing issues that might be accounted for
[18]
TME allows the inspection of the covariates dichotomiz-
ing them based in any of the previous options. In
particular, if the minimum p-value approach is used the
log-rank p-value can be corrected using either the
formula proposed by Altman et al [18] or with cross-
validation as proposed by Faraggi & Simon [20].
Additionally, TME implements the shrinkage method
proposed by Holländer et al [21] to correct the hazard
ratios.
Next version of TME will also include multivariate
analysis using a Cox proportional hazards model and
decision trees, which can easily accommodate hetero-
geneous variables and have yielded already satisfactory
results in the discovery of biomarkers for breast cancer
[22].
Data visualization
Data visualization was carried out using the publicly
available software tools Cytoscape, ClueGO, and GOlor-
ize. Cytoscape is free software package for visualizing,
modeling and analyzing molecular and genetic interac-
tion networks [23-26]. In Cytoscape, the nodes represent
genes or proteins and they are connected with edges
which representing interactions. Typical biological net-
works at the molecular level are gene regulation net-
works, signal transduction networks, protein interaction
networks, and metabolic networks. In order to capture
biological information, ClueGO [25], a Cytoscape plug-
in, uses Gene Ontology [27] categories that are over-
represented in selected one or two lists of genes. ClueGO
takes advantage of GOlorize [26] plug-in, an efficient
tool to the same class node-coloring and the class-
directed layout algorithm for advanced network visuali-
zation.
Discussion
In this paper we described computational tools devel-
oped specifically to address biological questions in
cancer immunology. The computational tools include:
1) a database for clinical and biomolecular data
comprising >1700 patients with associated clinical
information, FACS data, qPCR data, tissue microarray
data; 2) bioinformatics tools developed for the analyses
of medium and large-scale data, 3) statistical tools for
the survival analysis; and 4) tools for visualization of the
data. The power of the dedicated informatics solution is
leveraged by the integration of all computational
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resources using various interfaces. During the course of
the development of the database, the implementation of
the analytical tools, and the analysis of the data we have
learned several important lessons.
Lessons learned
First, development of a dedicated database is time-
consuming but indispensable task. In recent years, the
biology community has expended considerable effort to
confront the challenges of managing heterogeneous data
in a structured and organized way and as a result
developed information management systems for both
raw and processed data. Laboratory information man-
agement systems (LIMS) have been implemented for
handling data entry from robotic systems and tracking
samples as well as data management systems for
processed data including microarrays, proteomics data,
and microscopy data. In general, these sophisticated
systems are able to manage and analyze data generated
for only a single type or a limited number of
instruments, and were designed for only a specific type
of molecule. Thus, addressing a biological question
relying on several complementary technologies requires
a specific off-the-shelf database. It should be noted that
such a database could absorb several person-years of
software engineering and this effort tends to be under-
estimated.
Second, incorporation of clinical data poses additional
challenges. Many institutions have electronic patient
records and in principle, extracting the information
could be straightforward. However, technical, ethical,
and legal issues might delay or even prohibit the process
of data collection. Heterogeneous clinical and depart-
mental information systems, accessibility of patient data,
and managing sensitive information can introduce
several levels of complexity and require extensive
stakeholder discussions. A complex information man-
agement system that captures in a secure way the relevant
data is suggestive only for large (i.e. several hundred PIs)
institutions. The majority of the labs are better off with a
design of a relatively small, departmental database for
only few specific cohorts. The patient data should be first
de-identified and then provided to the biologists and
bioinformaticians.
Third, primary data should be archived at a separate
location and only preprocessed and normalized data
should be stored in the dedicated database. Although it
is tempting to upload and analyze all types of data in a
single system, experience shows that primary data is
mostly used once. This approach is even more advisable
for large-scale data including microarrays, proteomics of
sequence data. However, links to the primary data need
to be secured so that later re-analyses using improved
tools can be guaranteed. In this context it is noteworthy
that in the analyses we have performed so far only
medium-throughput data was used, meaning that the
number of analyzed molecular species was in the range
of 100-1000. With this number of elements the majority
of the tools perform satisfactorily on a standard desktop
computer. Performance is a crucial issue if the number of
molecules detected in a single patient sample increases
to >10.000 (like in microarray studies) or >100.000
(proteomics studies) and the used methods need to be
re-evaluated.
In this paper we show a powerful approach for
integrative analyses of heterogenous biomolecular data
and clinical data. Although powerful, our approach was
sequential, i.e. the data was integrated in the database
and the query masks allowed sequential analyses of
specific biomolecular data, and their correlation with
clinical data. We strongly believe that integrative data
analyses methods will provide additional insights
otherwise hidden in the complex data sets. Several
approaches were sugges ted prev ious ly (e .g .
[23-26,28-30]). However, normalization of the data,
availability of reference datasets, and scarcity of the data
(specific measurements are not available for all patients)
are non-trivial issues which are difficult to address. In
this context, novel data integration approaches are
highly desirable. In the following paragraphs we high-
light two approaches, namely biomolecular network
reconstruction and mathematical modelling, which have
the potential to provide mechanistic insights and
ultimately translation of this knowledge to clinical
applications.
Biomolecular network reconstruction
One emerging field, which was not addressed in this
paper is biomolecular network reconstruction. The data
we have so far used are actual measurements and are
limited to the available technology and/or samples.
There is a wealth of information stored in public
databases on protein-protein interactions, text mining,
two-hybrid screens, or gene silencing using siRNA. The
integration of this datasets in databases like STRING [31]
and the visualization tools like Cytoscape [23] and
associated-software such as ClueGO [25] opens new
avenues of exploration of biomolecular networks.
Mathematical modeling
Since the pathophysiological mechanisms underlying
cancer are highly complex and involve many different
cell types and processes, mathematical modeling is
becoming an important tool to integrate the biological
information and enhance our understanding of
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interaction between cancer and immune system. More-
over, mathematical modeling may direct direction of
experimental work for treatment and diagnosis. Here we
briefly describe relevant modeling efforts for tumour-
immune cells interaction.
Mathematical models of cancer
Traditionally, mathematical models of cancer fall into
two broad camps: descriptive and mechanistic [32].
Descriptive models tend to focus on reproducing the
gross characteristic of tumors such as size and cell
numbers, are generally used to investigate tumor cell
population dynamics, without emphasis on cell biolo-
gical detail [32-34]. Over the last decades, many
mathematical models have been proposed that focus
on tumor growth. Macklin et al. [35] performed a new
multiscale mathematical model for solid tumor growth
which couples an improved model of tumor invasion
with a model of tumor-induced angiogenesis. A large
number of studies have described deterministic models
which have been used to model the spatio-temporal
spread of tumors [36]. By contrast, mechanistic models
focus on specific aspects of tumor progression in order to
explain the underlying biological processes that drive
them [32,33,37].
Mathematical models of immune response
The regulation of immune system involves the interac-
tion between populations of pathogen and immune cell.
Immunological memory and specificity are property of
the immune system. This ability to respond more rapidly
and effective than to the first exposure [38]. Under-
standing of these aspects requires quantitative models of
proliferation and differentiation of T lymphocytes.
Mathematical modeling can describe these behaviors as
deterministic or stochastic models. De Boer et al.
proposed the simple mathematical model in which
parameters can be estimated (proliferation and death
rate) during clonal expansion and contraction phase
[39,40]. Three models have been proposed by Ganusov
[41] to discriminate between alternative memory cell
differentiation pathways.
Mathematical models of cancer-immune interactions
Mathematical modeling of tumor growth that includes
the immune response and chemotherapy treatment
would provide an analytical predictive framework. Kim
et al. developed a mathematical model with the new
experimental data to gain insights into the dynamics and
potential impact of the resulting anti-leukemia immune
response on chronic myelogenous leukemia (CML) [42].
Moore et al. modeled the interaction T cell subpopula-
tions and CML cancer cells in the body, using a system of
ordinary differential equations [43]. Steffen et al.
presented a mathematical model of melanoma invasion
into healthy tissue with an immune response. They used
this model as a framework with which to investigate
primary tumor invasion and treatment by surgical
excision [44].
Conclusion
In this paper we presented computational tools devel-
oped to manage and explore clinical and biomolecular
data for the identification of molecular mechanisms in
the tumor microenvironment. The presented bioinfor-
matics and statistics solutions were applied on a patient
cohort with colorectal cancer and revealed novel insights
in the tumor-immune cells interaction. Although used to
address a specific question, the approach is generic and
can be applied also to different cancers as well as to other
multifactorial diseases like diabetes or cardiovascular
diseases.
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